Molecular Cancer Therapeutics

Table of Contents

AACR American Association for Cancer Research

February 2016 • Volume 15 • Number 2

Highlights of This Issue 219

SMALL MOLECULE THERAPEUTICS

LARGE MOLECULE THERAPEUTICS

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

MODELS AND TECHNOLOGIES

Table of Contents

RETRACTION

ABOUT THE COVER

Orlistat is a FDA-approved antiobesity drug that shows anticancer effect in a wide range of cancers. However, off-target effects and poor bioavailability hinder its clinical translation as a repurposed new drug against triple-negative breast cancer (TNBC). Orlistat loaded in HEA-*b*-EHA polymeric micellar-nanoparticles improved the solubility, bioavailability, and therapeutic efficacy of orlistat *in vitro* in cells and *in vivo* in tumor xenografts of TNBC in mice. The cover image shows a schematic illustration of the orlistat-loaded HEA-*b*-EHA polymeric micelles with different functional moieties used for tumor targeting (folic acid) and imaging (DyLight-747-*B1*-NIR Dye) in living animals. The results of this study indicate that the orlistat packaged in HEA-*b*-EHA micellar-NP is a highly promising new drug formulation for TNBC therapy. For details, see the article by Paulmurugan and colleagues on page 221.



Molecular Cancer Therapeutics

15 (2)

Mol Cancer Ther 2016;15:219-344.